Core Viewpoint - The company reported a 13.4% year-on-year increase in revenue, reaching approximately HKD 310 million for the period ending June 30, 2025, alongside a record half-year profit of about HKD 76 million, reflecting a 12.7% year-on-year growth [1] Financial Performance - Revenue increased by 13.4% year-on-year to approximately HKD 310 million [1] - Half-year profit reached approximately HKD 76 million, marking a 12.7% year-on-year growth [1] - Earnings per share rose to approximately HKD 0.0127, reflecting a year-on-year increase of 16.5% [1] Strategic Focus - The company is refocusing its R&D strategy on the field of regenerative medicine [1] - It is exploring partnerships with leading regenerative medicine research institutions in China to develop innovative therapies utilizing growth factors and regenerative medicine technologies [1] - The aim is to leverage complementary strengths to accelerate research progress and further solidify the company's leadership position in biopharmaceutical innovation [1]